Message Font: Serif | Sans-Serif
No. of Recommendations: 0

Boston Scientific (BSX) : Ups to 3 STARS (hold) from 2 STARS (sell)
Analyst: Robert Gold

The shares are down this morning, after Boston Scientific issued an advisory to physicians about possible battery failure and malfunctions in certain defibrillator devices that were part of the operations of recently acquired Guidant. The number of failures seems to us mimimal relative to the number of implantations. We do not believe the development will impact the company's defibrillator sales, and think it acted appropriately. We are upping our 12-month target price by $1 to $21.
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.